Modulation of glucagon-like peptide-1 (GLP-1) potency by endocannabinoid-like lipids represents a novel mode of regulating GLP-1 receptor signaling

Journal of Biological Chemistry

Volumn 290, Issue 23, 2015, Pages 14302-14313

  Cheng, Yu Hong ^a   Ho, Mei Shang ^b   Huang, Wei Ting ^a   Chou, Ying Ting ^b   King, Klim ^a  

^a GENOMICS RESEARCH CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDES; BINDING ENERGY; BINS; HISTOLOGY; NEURODEGENERATIVE DISEASES; PEPTIDES; PHYSIOLOGY; TISSUE;

CONFORMATIONAL CHANGE; ENDOCANNABINOID; GLUCAGON-LIKE PEPTIDE-1; NEURONAL TISSUES; OLEOYLETHANOLAMIDE; RECEPTOR BINDING; RECEPTOR SIGNALING; TYPE-2 DIABETES;

LIPIDS;

2 OLEOYLGLYCEROL; AMIDE; CYCLIC AMP; ENDOCANNABINOID; GLUCAGON LIKE PEPTIDE 1; N OLEOYLETHANOLAMINE; PALMIDROL; STEAROYLETHANOLAMIDE; TRYPSIN; UNCLASSIFIED DRUG; 2-OLEOYLGLYCEROL; ACYLGLYCEROL; GLP1R PROTEIN, HUMAN; GLP1R PROTEIN, RAT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; OLEIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; GENE INACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION; ANIMAL; HUMAN; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLIC AMP; ENDOCANNABINOIDS; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLYCERIDES; HUMANS; OLEIC ACIDS; RATS; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 84930660533     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.655662     Document Type: Article

References (49)

1. Hamilton, A., and Hölscher, C. (2009) Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 20, 1161-1166
2. Lockie, S. H. (2013) Glucagon-like peptide-1 receptor in the brain: role in neuroendocrine control of energy metabolism and treatment target for obesity. J. Neuroendocrinol. 25, 597-604
3. Merchenthaler, I., Lane, M., and Shughrue, P. (1999) Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261-280
4. Campbell, J. E., and Drucker, D. J. (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 17, 819-837
5. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., and Foltynie, T. (2014) Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-344
6. Hölscher, C. (2014) Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 221, T31-T41
7. Lønborg, J., Kelbæk, H., Vejlstrup, N., Bøtker, H. E., Kim, W. Y., Holmvang, L., Jørgensen, E., Helqvist, S., Saunamäki, K., Terkelsen, C. J., Schoos, M. M., Køber, L., Clemmensen, P., Treiman, M., and Engstrøm, T. (2012) Exenatide reduces final infarct size in patients with ST-segmentelevation myocardial infarction and short-duration of ischemia. Circ. Cardiovasc. Interv. 5, 288-295
8. Orskov, C. (1992) Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 35, 701-711
9. Nadkarni, P., Chepurny, O. G., and Holz, G. G. (2014) Regulation of glucose homeostasis by GLP-1. Prog. Mol. Biol. Transl. Sci. 121, 23-65
10. Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., and Gallwitz, B. (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53, 654-662
11. Gu, G., Roland, B., Tomaselli, K., Dolman, C. S., Lowe, C., and Heilig, J. S. (2013) Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J. Comp. Neurol. 521, 2235-2261
12. Larsen, P. J., Tang-Christensen, M., Holst, J. J., and Orskov, C. (1997) Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77, 257-270
13. Llewellyn-Smith, I. J., Gnanamanickam, G. J., Reimann, F., Gribble, F. M., and Trapp, S. (2013) Preproglucagon (PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem. Neuroscience 229, 130-143
14. Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., and Trapp, S. (2011) Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 180, 111-121
15. Widmann, C., Bürki, E., Dolci, W., and Thorens, B. (1994) Signal transduction by the cloned glucagon-like peptide-1 receptor: comparison with signaling by the endogenous receptors of β cell lines. Mol. Pharmacol. 45, 1029-1035
16. Mayo, K. E., Miller, L. J., Bataille, D., Dalle, S., Göke, B., Thorens, B., and Drucker, D. J. (2003) International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55, 167-194
17. Ezzili, C., Otrubova, K., and Boger, D. L. (2010) Fatty acid amide signaling molecules. Bioorg. Med. Chem. Lett. 20, 5959-5968
18. Vaughn, L. K., Denning, G., Stuhr, K. L., de Wit, H., Hill, M. N., and Hillard, C. J. (2010) Endocannabinoid signalling: has it got rhythm? Br. J. Pharmacol. 160, 530-543
19. Roberts, C. J., Stuhr, K. L., and Hillard, C. J. (2012) Swim stress differentially affects limbic contents of 2-arachidonoylglycerol and 2-oleoylglycerol. Neuroscience 204, 74-82
20. Loening, A. M., Fenn, T. D., Wu, A. M., and Gambhir, S. S. (2006) Consensus guided mutagenesis of Renilla luciferase yields enhanced stability and light output. Protein Eng. Des. Sel. 19, 391-400
21. Hsu, Y. Y., Liu, Y. N., Lu, W. W., and Kung, S. H. (2009) Visualizing and quantifying the differential cleavages of the eukaryotic translation initiation factors eIF4GI and eIF4GII in the enterovirus-infected cell. Biotechnol. Bioeng. 104, 1142-1152
22. Jiang, L. I., Collins, J., Davis, R., Lin, K. M., DeCamp, D., Roach, T., Hsueh, R., Rebres, R. A., Ross, E. M., Taussig, R., Fraser, I., and Sternweis, P. C. (2007) Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway. J. Biol. Chem. 282, 10576-10584
23. Barak, L. S., Salahpour, A., Zhang, X., Masri, B., Sotnikova, T. D., Ramsey, A. J., Violin, J. D., Lefkowitz, R. J., Caron, M. G., and Gainetdinov, R. R. (2008) Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol. Pharmacol. 74, 585-594
24. Bacart, J., Corbel, C., Jockers, R., Bach, S., and Couturier, C. (2008) The BRET technology and its application to screening assays. Biotechnol. J. 3, 311-324
25. Bhathena, S. J., Oie, H. K., Gazdar, A. F., Voyles, N. R., Wilkins, S. D., and Recant, L. (1982) Insulin, glucagon, and somatostatin receptors on cultured cells and clones from rat islet cell tumor. Diabetes 31, 521-531
26. Philippe, J., Chick, W. L., and Habener, J.F. (1987) Multipotential phenotypic expression of genes encoding peptide hormones in rat insulinoma cell lines. J. Clin. Invest. 79, 351-358
27. Korman, L. Y., Bhathena, S. J., Voyles, N. R., Oie, H. K., and Recant, L. (1985) Characteristics of the interaction of the glucagon receptor, cAMP, and insulin secretion in parent cells and clone 5F of a cultured rat insulinoma. Diabetes 34, 717-722
28. Gallwitz, B., Witt, M., Fölsch, U. R., Creutzfeldt, W., and Schmidt, W. E. (1993) Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J. Mol. Endocrinol. 10, 259-268
29. Oakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., and Caron, M. G. (1999) Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J. Biol. Chem. 274, 32248-32257
30. Kerr, B.D., Flatt, A. J., Flatt, P.R., and Gault, V. A. (2011) Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 404, 870-876
31. Unson, C. G., Andreu, D., Gurzenda, E. M., and Merrifield, R. B. (1987) Synthetic peptide antagonists of glucagon. Proc. Natl. Acad. Sci. U.S.A. 84, 4083-4087
32. Gefel, D., Hendrick, G. K., Mojsov, S., Habener, J., and Weir, G. C. (1990) Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3',5'-monophosphate formation. Endocrinology 126, 2164-2168
33. Salahpour, A., Espinoza, S., Masri, B., Lam, V., Barak, L. S., and Gainetdinov, R. R. (2012) BRET biosensors to study GPCR biology, pharmacology, and signal transduction. Front. Endocrinol. 10.3389/fendo.2012.00105
34. Overton, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C., Gardner, L. S., Griffin, G., Jackson, H. C., Procter, M. J., Rasamison, C. M., Tang-Christensen, M., Widdowson, P. S., Williams, G. M., and Reynet, C. (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3, 167-175
35. Chu, Z. L., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M., Gao, H., Mondala, H., Bagnol, D., Unett, D., Liang, Y., Demarest, K., Semple, G., Behan, D. P., and Leonard, J. (2007) A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148, 2601-2609
36. Ning, Y., O'Neill, K., Lan, H., Pang, L., Shan, L. X., Hawes, B. E., and Hedrick, J. A. (2008) Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br. J. Pharmacol. 155, 1056-1065
37. Adelhorst, K., Hedegaard, B. B., Knudsen, L. B., and Kirk, O. (1994) Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 269, 6275-6278
38. Robinson, R. M., Blakeney, E. W., Jr., and Mattice, W. L. (1982) Lipid-induced conformational changes in glucagon, secretin, and vasoactive intestinal peptide. Biopolymers 21, 1217-1228
39. Parthier, C., Reedtz-Runge, S., Rudolph, R., and Stubbs, M. T. (2009) Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci. 34, 303-310
40. Trapp, S., and Richards, J. E. (2013) The gut hormone glucagon-like peptide-1 producedinbrain: isthis physiologically relevant? Curr. Opin. Pharmacol. 13, 964-969
41. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., and Foltynie, T. (2013) Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736
42. Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., and Gong, C. X. (2013) Subcutaneous administrationofliraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J. Alzheimers Dis. 37, 637-648
43. Kleberg, K., Hassing, H. A., and Hansen, H. S. (2014) Classical endocannabinoid-like compounds and their regulation by nutrients. Biofactors 40, 363-372
44. Hara, T., Kimura, I., Inoue, D., Ichimura, A., and Hirasawa, A. (2013) Free fatty acid receptors and their role in regulation of energy metabolism. Rev. Physiol. Biochem. Pharmacol. 164, 77-116
45. Hermanson, D. J., Hartley, N. D., Gamble-George, J., Brown, N., Shonesy, B. C., Kingsley, P. J., Colbran, R. J., Reese, J., Marnett, L. J., and Patel, S. (2013) Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat. Neurosci. 16, 1291-1298
46. Richardson, D., Ortori, C. A., Chapman, V., Kendall, D. A., and Barrett, D. A. (2007) Quantitative profiling of endocannabinoids and related compounds in rat brain using liquid chromatography-tandem electrospray ionization mass spectrometry. Anal. Biochem. 360, 216-226
47. Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., and Knop, F. K. (2013) Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56, 965-972
48. Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., and Vilsbøll, T. (2011) Impaired regulation of the incretin effect in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 96, 737-745
49. Wiedenkeller, D.E., and Sharp, G. W.(1983) Effects of forskolin on insulin release and cyclic AMP contentin rat pancreatic islets. Endocrinology113, 2311-2313